Stage IVC Squamous Cell Carcinoma of the Larynx Completed Phase 1 / 2 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0029837 (Stage IVC Squamous Cell Carcinoma of the Larynx)Completed1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00063895Erlotinib in Treating Patients With Advanced Non-Small Cell Lung Cancer, Ovarian Cancer, or Squamous Cell Carcinoma of the Head and NeckTreatment